Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: Tocilizumab reduces corrected qt interval by controlling systemic inflammation

Arthritis Care and Research

Volumn 67, Issue 3, 2015, Pages 332-339

  Lazzerini, Pietro Enea ^a   Acampa, Maurizio ^b   Capecchi, Pier Leopoldo ^a   Fineschi, Irene ^a   Selvi, Enrico ^a   Moscadelli, Valentina ^a   Zimbone, Stefania ^a   Gentile, Daniela ^a   Galeazzi, Mauro ^a   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIARRHYTHMIC AGENT; ANTIRHEUMATIC AGENT; AUTACOID; CYTOKINE; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; QT INTERVAL; QT PROLONGATION; RHEUMATOID ARTHRITIS; RISK REDUCTION; TREATMENT DURATION; ACTION POTENTIAL; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; ARTHRITIS, RHEUMATOID; BLOOD; COMPLICATION; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME;

ACTION POTENTIALS; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARRHYTHMIAS, CARDIAC; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CYTOKINES; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923290031     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22455     Document Type: Article

References (27)

1. John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med 2012;23:575-9.
2. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52: 402-11.
3. Bergner DW, Goldberger JJ. Diabetes mellitus and sudden cardiac death: what are the data? Cardiol J 2010;17:117-29.
4. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-331.
5. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Eng J Med 2001;345:1473-82.
6. Li YH, Rozanski GJ. Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res 1993;27:525-30.
7. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z. Impairment of HERG K(+) channel function by tumor necrosis factor-α: role of reactive oxygen species as a mediator. J Biol Chem 2004;279:13289-92.
8. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 2006;290:H2098-107.
9. Kawada H, Niwano S, Niwano H, Yumoto Y, Wakisaka Y, Yuge M, et al. Tumor necrosis factor-α downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. Circ J 2006;70:605-9.
10. Hagiwara Y, Miyoshi S, Fukuda K, Nishiyama N, Ikegami Y, Tanimoto K, et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 2007; 43:710-16.
11. Fernandez-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. TNF-α downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Am J Physiol Heart Circ Physiol 2007;293:H238-45.
12. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, et al. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med 2013;24:368-74.
13. Chauhan K, Ackerman M, Crowson CS, Matteson EL, Gabriel SE. Prolongation of QT interval in patients with rheumatoid arthritis and its impact on mortality: results from a population-based study [abstract]. Arthritis Rheum 2013;65 Suppl 10:S160.
14. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, et al. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology 2014;53:131-7.
15. Smolen, JS, Schoels MM, Nishimoto N, Breedveld FC, Bufrmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.
16. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal." J Cardiovasc Electrophysiol 2006;17:33333-6.
17. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. Part IV: the ST segment, T and U waves, and the QT interval. A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:982-91.
18. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-1894.
19. De Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J 1999;20:278-84.
20. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7.
21. El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J 2011;18:233-45.
22. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation 2009;119:663-70.
23. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev 2014;13:936-44.
24. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am J Physiol Heart Circ Physiol 2003;284: H431-41.
25. Panama BK, Latour-Villamil D, Farman GP, Zhao D, Bolz SS, Kirshenbaum LA, et al. Nuclear factor κB downregulates the transient outward potassium current I(to,f) through control of KChIP2 expression. Circ Res 2011;108:537-43.
26. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
27. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992;127:25-50.